Published in J Clin Oncol on January 01, 1996
Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer (2000) 1.20
Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol (2008) 0.92
Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol (2008) 0.89
STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma. Int J Oncol (2012) 0.88
Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol (2013) 0.83
The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study. PLoS One (2015) 0.83
Biomarkers in cervical cancer. Biomark Insights (2007) 0.81
Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J Clin Pathol (2007) 0.81
Serum biomarkers for early detection of gynecologic cancers. Cancers (Basel) (2010) 0.80
Squamous cell carcinoma antigen in cervical cancer and beyond. J Gynecol Oncol (2013) 0.80
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities. Int J Proteomics (2011) 0.78
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. PLoS One (2016) 0.78
A Novel Controlled Release Immunosensor based on Benzimidazole Functionalized SiO2 and Cyclodextrin Functionalized Gold. Sci Rep (2016) 0.77
Could the extent of lymphadenectomy be modified by neoadjuvant chemotherapy in cervical cancer? A large-scale retrospective study. PLoS One (2015) 0.76
Relationship between pre-treatment serum SCC (squamous cell carcinoma) antigen, Cyfra 21-1 levels, and survival in squamous cell carcinoma of the uterine cervix. Cancer Res Treat (2005) 0.75
The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. Obstet Gynecol Sci (2015) 0.75
Can ABCF2 protein expression predict the prognosis of uterine cancer? Br J Cancer (2008) 0.75
Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol (2017) 0.75
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20
Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol (1996) 2.94
Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. BMJ (1993) 2.50
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet (1999) 2.27
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Inhibin as a marker for granulosa-cell tumors. N Engl J Med (1989) 1.97
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol (1987) 1.71
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
Malignant struma ovarii treated by ovariectomy, thyroidectomy, and 131I administration. Cancer (1987) 1.50
Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth J Med (2005) 1.50
The Frenchay Activities Index. Assessment of functional status in stroke patients. Stroke (1993) 1.47
Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol (2003) 1.46
First trimester CA 125 and Down's syndrome. Br J Obstet Gynaecol (1991) 1.41
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol (2002) 1.39
[Home treatment of patients with cerebrovascular accidents]. Ned Tijdschr Geneeskd (1993) 1.39
Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut (2002) 1.38
CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol (1986) 1.33
The long-term course of shoulder complaints: a prospective study in general practice. Rheumatology (Oxford) (1999) 1.32
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol (1984) 1.28
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst (1995) 1.21
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol (2009) 1.16
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Predictive value of human papillomavirus type for histological diagnosis of women with cervical cytological abnormalities. BMJ (1995) 1.16
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol (1987) 1.15
Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer (1987) 1.14
Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol (2001) 1.14
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer (2004) 1.14
Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol (2001) 1.14
A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet (2001) 1.11
The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol (1995) 1.11
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol (1995) 1.10
The influence of cardiovascular disease on quality of life in type 2 diabetics. Qual Life Res (2002) 1.08
The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res (2001) 1.08
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol (2005) 1.08
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol (2003) 1.08
Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer (1999) 1.06
Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). Neth J Med (2005) 1.06
A shoulder pain score: a comprehensive questionnaire for assessing pain in patients with shoulder complaints. Scand J Rehabil Med (1996) 1.06
The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol (1990) 1.04
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (2001) 1.02
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol (2000) 1.02
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol (2007) 1.01
Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol (1990) 1.00
Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol (2000) 1.00
Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br J Cancer (1996) 0.98
Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med (2010) 0.98
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer (1994) 0.97
Family doctor-driven follow-up for adult childhood cancer survivors supported by a web-based survivor care plan. J Cancer Surviv (2011) 0.97
Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res (1999) 0.97
Bacterial vaginosis is not important in the etiology of cervical neoplasia: a survey on women with dyskaryotic smears. Sex Transm Dis (1996) 0.97
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol (1998) 0.96
Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol (1995) 0.96
Health-related quality of life and adverse late effects in adult (very) long-term childhood cancer survivors. Eur J Cancer (2006) 0.95
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95
Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol (2007) 0.95
Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology (2004) 0.95
Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer (2001) 0.95
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res (1991) 0.95